|Other Names||Visinin-like protein 1, VILIP, VLP-1, Hippocalcin-like protein 3, HLP3, VSNL1, VISL1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1561a was selected from the C-term region of human VILIP1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Regulates (in vitro) the inhibition of rhodopsin phosphorylation in a calcium-dependent manner.|
|Tissue Location||Brain and retina. Neuron-specific in the central and peripheral nervous system. Increased in the cerebrospinal fluid of Alzheimer disease patients (at protein level).|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The visinin and visinin-like peptides represent a family of calcium-binding proteins that are highly expressed in the retina. Visinin has been shown to be a cone cell-specific protein with a molecular weight of 24 kDa. Several members of the visinin family of genes have been isolated and characterized from different species. These peptides are believed to be involved in the processes of phototransduction. The recoverin gene (RCV1) is believed to be involved in the pathophysiology of retinopathy in cancer patients.
Braunewell, K.H., et al., Neuropharmacology 44(6):707-715 (2003).Lin, L., et al., J. Biol. Chem. 277(44):41872-41878 (2002).Spilker, C., et al., J. Neurosci. 22(17):7331-7339 (2002).Bernstein, H.G., et al., Neuroreport 13(4):393-396 (2002).Lin, L., et al., Biochem. Biophys. Res. Commun. 296(4):827-832 (2002).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.